High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 63: | Line 63: | ||
|- | |- | ||
| [[Oxford Niaspan Study]] | | [[Oxford Niaspan Study]] | ||
|- | |||
| Coronary Drug Project | |||
|- | |||
| Stockholm Ischemic Heart Disease Study | |||
|- | |||
| FATS | |||
|- | |||
| FATS Extended follow-up | |||
|- | |||
| UCSF-SCOR | |||
|- | |- | ||
|} | |} | ||
Revision as of 14:26, 8 October 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein landmark trials On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
|
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CETP Inhibitors
| ACCELERATE Trial |
| Dal-OUTCOMES Trial |
| Dal-VESSEL Trial |
| Dal-PLAQUE Trial |
| DEFINE Trial |
| ILLUMINATE Trial |
| ILLUSTRATE Trial |
| REVEAL Trial |
| REVEAL HPS-3 TIMI-55 trial |
| RADIANCE 1 |
| RADIANCE 2 |
Niacin
| AIM-HIGH Trial |
| ARBITER 2 Trial |
| ARBITER 3 Trial |
| ARBITER 6-HALTS Trial |
| CLAS Trial |
| HATS Trial |
| Oxford Niaspan Study |
| Coronary Drug Project |
| Stockholm Ischemic Heart Disease Study |
| FATS |
| FATS Extended follow-up |
| UCSF-SCOR |
Fibrate
| VA-HIT Trial |
| BECAIT Trial |
| BIP Trial |
Statin
| ASTEROID Trial |
| SATURN Trial |
| 4S Trial |
| CORONA Trial |
Multiple Lipid Lowering Drugs
| HARP Study |
| AFREGS Trial |